Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Sarcoma 40Neoplasm Metastasis 7Leiomyosarcoma 7Liposarcoma 6Hemangiosarcoma 6Neurofibrosarcoma 5Sarcoma, Synovial 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Glioblastoma 4Dermatofibrosarcoma 4Chondrosarcoma, Extraskeletal Myxoid 4Sarcoma, Alveolar Soft Part 3Neoplasms 3Gliosarcoma 3Gastrointestinal Stromal Tumors 3Fibrosarcoma 3Breast Neoplasms 3Brain Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nerve Sheath Neoplasms 2Histiocytoma, Angiomatoid Fibrous 2Hemangioendothelioma, Epithelioid 2Granuloma, Plasma Cell 2Carcinoma, Renal Cell 2

Interventions

seclidemstat 2Topotecan 2Cyclophosphamide 2selinexor 1pazopanib 1Zoledronic Acid 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × pazopanib × Sarcoma × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡